Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis

References

• Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008;65:1703-10
   PubMed Web of Science ®Google Scholar
• Untch M, Lück HJ. Lapatinib – member of a new generation of ErbB-targeting drugs. Breast Care (Basel) 2010;5:8-12
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst 2013;25:165-71
   PubMedGoogle Scholar
• Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655
   PubMed Web of Science ®Google Scholar
• Tykerb (lapatinib) FDA prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf [Last accessed 1 December 2013]
   Google Scholar
• Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013;58:3389-96
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta analysis. Expert Opinion Drug Saf 2014;13:999-1008
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013;31:4504-11
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
   PubMed Web of Science ®Google Scholar
• National cancer institute. Common toxicity criteria. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf [Last accessed 1 December 2014]
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Robidoux A, Tang G, Rastogi P. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183-92
   PubMed Web of Science ®Google Scholar
• Guarneri V, Frassoldati A, Bottini A. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-95
   PubMed Web of Science ®Google Scholar
• Untch M, Loibl S, Bischoff J. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135-44
   PubMed Web of Science ®Google Scholar
• DeCensi A, Puntoni M, Pruneri G. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011;4:1181-9
   PubMed Web of Science ®Google Scholar
• Ravaud A, Hawkins R, Gardner JP. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008;26:2285-91
   PubMed Web of Science ®Google Scholar
• Goss PE, Smith IE, O’shaughnessy J. Adjuvant lapatinib for women with early-stage HER2- positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:88-96
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40
   PubMed Web of Science ®Google Scholar
• Johnston SR, Gómez H, Stemmer SM. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137:755-66
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Johnston SR, Manikhas A, et al. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 2013;137:471-82
   PubMed Web of Science ®Google Scholar
• Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013;49:3763-72
   PubMed Web of Science ®Google Scholar
• Lin NU, Eierman W, Greil R. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011;105:613-20
   PubMed Web of Science ®Google Scholar
• Schwarzberg LS, Franco SX. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J, Pivot X. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, doubleblind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Del Campo JM, Hitt R, Sebastian P. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011;105:618-27
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas lopez L, Zarba JJ. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9
   PubMed Web of Science ®Google Scholar
• Harrington K, Berrier A, Robinson M, et al. Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013;49:1609-18
   PubMed Web of Science ®Google Scholar
• Hicks DG, Whitney-Miller CL. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. Biotech Histochem 2013;88:121-31
   PubMed Web of Science ®Google Scholar
• Cui H, Cheng Y, Piao SZ, et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int 2014;14:10
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 2006;66:1630-9
   PubMed Web of Science ®Google Scholar
• Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for firstline treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013;31:3926-34
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egyptian Nat Cancer Inst 2014;26:9-13. doi: 10.1016/j.jnci.2013.08.003
   Google Scholar
• Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit Rev Oncol Hematol 2014;91:1-8 doi: 10.1016/j.critrevonc.2013.12.013
   Google Scholar
• Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Canc 2011;19:1667-74
   PubMed Web of Science ®Google Scholar
• Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011;22:524-35
   PubMed Web of Science ®Google Scholar
• Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Canc 2013;108:1985-93
   PubMed Web of Science ®Google Scholar
• Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Canc 2013;110:55-62
   PubMed Web of Science ®Google Scholar
• Newman M, Gerami P, Guitart J, et al. Histological differentiation of skin toxicity between cetuximab, erlotinib and panitumumab (single ErbB1) and lapatinib (dual ErbB1/2) epidermal growth factor receptor inhibitors. J Clin Oncol (Meeting Abstracts) 2009;27:e20617
   Google Scholar
• Nardone B, Kaklamani VG, Nicholson KM, et al. Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl):2581
   Google Scholar
• Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013;69:708-20
   PubMed Web of Science ®Google Scholar